Anthrax future or investigational therapies

Anthrax Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Anthrax from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Anthrax future or investigational therapies On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Anthrax future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Anthrax future or investigational therapies
CDC on Anthrax future or investigational therapies
Anthrax future or investigational therapies in the news
Blogs on Anthrax future or investigational therapies
Directions to Hospitals Treating Anthrax
Risk calculators and risk factors for Anthrax future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Given the safety and efficacy of current vaccines and antibiotics, there are not a large number of new agents under development to treat anthrax.

Newer Agents

In recent years there have been many attempts to develop additional new drugs to prevent anthrax; however the existing supply of current antibiotics is effective if treatment is initiated soon after infection has occurred.

In May 2009, Human Genome Sciences submitted a Biologic License Application (BLA, permission to market) for its new drug, raxibacumab (brand name ABthrax) intended for emergency treatment of inhaled anthrax.